TY - JOUR
T1 - Prediction of invasive activities in hepatocellular carcinomas with special reference to α-fetoprotein and des-γ-carboxyprothrombin
AU - Gotoh, Miki
AU - Nakatani, Tomohiro
AU - Masuda, Taizo
AU - Mizuguchi, Yasunori
AU - Sakamoto, Michiie
AU - Tsuchiya, Ryosuke
AU - Kato, Hoichi
AU - Furuta, Koh
PY - 2003/10/1
Y1 - 2003/10/1
N2 - Background: Hepatocellular carcinoma (HCC) is one of the world's major malignancies, especially in Asian countries. To improve the prognosis of HCC, it is essential to predict its invasive behavior in both intra- and extra-hepatic modalities. For this purpose, we examined the predictive values of two tumor markers, α-fetoprotein (AFP) and des-γ-carboxyprothrombin (DCP). Methods: 194 HCC cases at the National Cancer Center Hospital were selected from the Pathology Records. Detailed information regarding the existence of extra-hepatic venous invasion (EHVI) at the portal vein and intra-hepatic multiple malignant tumors (IHMTs) were collected and combined with the preoperative AFP and DCP testing results. Furthermore, information about the viral infection status such as HBs antigen positive or HCV antibody positive or no viral hepatitis was obtained. The information was analyzed by the ROC (Receiver Operating Characteristic Curve) method. Results and conclusions: In both the EHVI group and the IHMT group, all the combinations except the HCV-positive group of IHMT revealed a tendency for DCP to offer better diagnostic accuracies, although this was statistically significant only in the HBs-positive group of IHMT. This result indicates either (1) that in a strict sense, DCP is not necessarily better than AFP at predicting the invasive characteristics or (2) that DCP is better than AFP at reflecting the invasive characteristics of HCC although not statistically significant. In either situation, from a long-term viewpoint, it is advisable to find a new marker or to re-evaluate the existing markers in order to predict the invasive characteristics more accurately.
AB - Background: Hepatocellular carcinoma (HCC) is one of the world's major malignancies, especially in Asian countries. To improve the prognosis of HCC, it is essential to predict its invasive behavior in both intra- and extra-hepatic modalities. For this purpose, we examined the predictive values of two tumor markers, α-fetoprotein (AFP) and des-γ-carboxyprothrombin (DCP). Methods: 194 HCC cases at the National Cancer Center Hospital were selected from the Pathology Records. Detailed information regarding the existence of extra-hepatic venous invasion (EHVI) at the portal vein and intra-hepatic multiple malignant tumors (IHMTs) were collected and combined with the preoperative AFP and DCP testing results. Furthermore, information about the viral infection status such as HBs antigen positive or HCV antibody positive or no viral hepatitis was obtained. The information was analyzed by the ROC (Receiver Operating Characteristic Curve) method. Results and conclusions: In both the EHVI group and the IHMT group, all the combinations except the HCV-positive group of IHMT revealed a tendency for DCP to offer better diagnostic accuracies, although this was statistically significant only in the HBs-positive group of IHMT. This result indicates either (1) that in a strict sense, DCP is not necessarily better than AFP at predicting the invasive characteristics or (2) that DCP is better than AFP at reflecting the invasive characteristics of HCC although not statistically significant. In either situation, from a long-term viewpoint, it is advisable to find a new marker or to re-evaluate the existing markers in order to predict the invasive characteristics more accurately.
KW - Des-γ-carboxyprothrombin
KW - Hepatocellular carcinoma
KW - Receiver Operating Characteristic Curve
KW - Venous invasion
KW - α-fetoprotein
UR - http://www.scopus.com/inward/record.url?scp=0642342305&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0642342305&partnerID=8YFLogxK
U2 - 10.1093/jjco/hyg096
DO - 10.1093/jjco/hyg096
M3 - Article
C2 - 14623921
AN - SCOPUS:0642342305
SN - 0368-2811
VL - 33
SP - 522
EP - 526
JO - Japanese Journal of Clinical Oncology
JF - Japanese Journal of Clinical Oncology
IS - 10
ER -